Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), and have a lower Charlson comorbidity score (2.6 vs 2.8) compared with those ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...

Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.

EMBARGOED: Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research that ...

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly ...

Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...

Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. The April 20, 2013 ...

SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product ...